Clinical Forum for Operational Excellence 2016

DIA27 - 28 October 2016, Dusseldorf, Germany.
Clinical Data, Clinical Operations and Statistics are highly dynamic groups in the clinical development arena. 2016 will bring important changes in the European regulatory framework once the ICH E6 Addendum kicks in with the following guidances:
  • Sponsors will be expected to implement a system to manage quality throughout the design, conduct, recording, evaluation, reporting and archiving of clinical trials.
  • The sponsor should ensure that all aspects of the trial are operationally feasible and should avoid unnecessary complexity, procedures and data collection. Protocols, case report forms, and other operational documents should be clear, concise and consistent.
  • The sponsor should ensure oversight of any trial-related duties and functions carried out on its behalf. The sponsor should develop a systematic, prioritized, risk-based appraoch to monitoring clinical trials. A combination of on-site and centralized monitoring activities may be appropriate. The sponsor should document the rationale for the chosen monitoring strategy (e.g. in the monitoring plan).

These changes will impact how we manage clincial development operationally with quality embedded through operational excellence not a goal but an expectation.

In three parallel themes, Data Management, Clinical Operations and Statistics will be examined through presentation, case studies and discussion focusing on how to achieve operational excellence. During a joint plenary session, topics that bind both groups will be discussed: Risk-based Monitoring, the status of eSource and independent 3rd parties, and Quality Management in Outsourcing.

Who should attend?

  • Professional working with clinical operations
  • Clinical data management professionals
  • Monitors
  • Statisticians
  • Inspectors
  • Process optimization leads and managers
  • Trial managers
  • Field monitors
  • Site representetatives, Site leads
  • Project data managers
  • Professionals working in the interface between CROs and Sponsors
  • Vendor managers
  • Pharma IT professionals (working in highly regulated environment)

For further information, please visit:
http://www.diaglobal.org/en/conference-listing/meetings/2016/10/9th-annual-clinical-forum-13-14-oct-2016-dusseldorf-germany

About DIA
For over 50 years, DIA has served as a global platform for more than 30,000 health care product development professionals, researchers, regulators, clinicians, academics and patient advocates to collaborate to improve health globally through the advancement of lifesaving medicines and technologies. As the premier professional community for the health care product development ecosystem, DIA (the Drug Information Association) provides global players a neutral and transparent forum for the exchange of ideas and collaboration. By offering access to tools, resources, and networking opportunities, DIA provides its members and international participants objective opportunities for extending debate and discussion to advance scientific and medical innovation.

DIA is an independent, global nonprofit organization based in Washington, DC, USA, with regional offices representing the Americas (Horsham, PA, USA); Europe, the Middle East, and Africa (Basel, Switzerland); and Asia (Beijing, China; Mumbai, India; and, Tokyo, Japan).

Most Popular Now

Pfizer and Lilly announce top-line results from lo…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the stu...

Bristol-Myers Squibb reports first quarter financi…

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (a...

Walnuts may help lower blood pressure for those at…

When combined with a diet low in saturated fats, eating walnuts may help lower blood pressure in people at risk for cardiovascular disease, according to a new Penn State ...

Amgen ignites a social fitness movement to support…

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support t...

Comprehensive tumor profiling promises new therape…

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave...

AstraZeneca starts artificial intelligence collabo…

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treat...

Possible link between autism and antidepressants u…

An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in t...

Chemotherapy or not?

Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how "smart" diagnostic-imaging machi...

Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the con...

Drugs to prevent stroke and dementia show promise …

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study...

Amgen and Syapse enter precision medicine collabor…

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precisio...

Personalizing precision medicine with combination …

Precision oncology often relies on treating patients with a single, molecularly matched therapy that targets one mutation in their tumor. In a report, published online in...